Yes, chemotherapy for breast cancer absolutely causes peripheral neuropathy—it is a well-established, common, and potentially debilitating complication.
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious clinical problem caused by several cytotoxic drugs commonly used in breast cancer treatment, particularly taxanes (paclitaxel, docetaxel), platinums (cisplatin, carboplatin), vinca alkaloids, epothilones, eribulin, and bortezomib 1.
Incidence and Clinical Impact
The prevalence of CIPN in breast cancer patients is substantial:
- 67.7% of patients develop some degree of neuropathy (NCI-CTCAE Grade ≥1) after completing just two cycles of taxane- or platinum-based chemotherapy 2
- 34.4% develop clinically meaningful neuropathy (Grade ≥2 or higher) 2
- 41.9% of patients still report peripheral neuropathy two years after treatment initiation, demonstrating the long-term nature of this toxicity 3
CIPN markedly affects quality of life and can be detrimental to cancer outcomes by limiting the amount of chemotherapy that can be administered 1. Patients with moderate-to-severe CIPN have significantly higher distress scores (mean 6.17) compared to those with mild or no neuropathy (4.21 and 4.04 respectively, p<0.001) 4.
Clinical Presentation: What to Look For
Taxane-Induced Neuropathy (Paclitaxel/Docetaxel)
Acute phase (occurs within days of each dose):
- Pain syndrome peaking 2-3 days after infusion
- Primarily truncal/hip distribution pain
- Previously mislabeled as "arthralgias/myalgias" but now recognized as acute neuropathy 1
Chronic phase:
- Primarily sensory neuropathy (not motor or autonomic)
- Numbness and tingling appear first and are more prominent than pain
- Stocking-glove distribution starting distally in fingers and toes, progressing proximally
- More prominent in lower extremities than upper extremities during treatment 1
- Symptoms tend to improve over several months after chemotherapy completion 1
Platinum-Induced Neuropathy (Oxaliplatin)
Acute phase:
- Cold sensitivity
- Throat discomfort and difficulty swallowing cold liquids
- Muscle cramps
- Symptoms peak 2-3 days after each dose
- Severity doubles with each subsequent cycle
- Does not return to baseline between cycles 1
Chronic phase:
- Similar sensory symptoms (numbness, tingling, pain)
- More severe in upper extremities than lower extremities during treatment
- "Coasting phenomenon": symptoms worsen for 2-3 months after stopping chemotherapy, then begin to improve 1
- After several months, neuropathy becomes worse in feet than hands
- Can remain a substantial debilitating problem for years in a subset of patients 1
Risk Factors for Severe CIPN
Clinicians should assess these factors before initiating neurotoxic chemotherapy 1:
- Pre-existing neuropathy
- Diabetes mellitus
- Family or personal history of hereditary neuropathy
- Older age (≥65 years)
- Obesity
- Higher cumulative chemotherapy doses
- Taxane-platinum combination therapy
- Greater number of positive lymph nodes
- Mastectomy (vs. lumpectomy) 3, 2
Diagnosis
The diagnosis can generally be made by clinical history alone 1. If a patient receiving neurotoxic chemotherapy develops new or worsening numbness, tingling, and/or pain in hands and/or feet without another clear etiology, the diagnosis is established.
Neurophysiological testing (EMG, nerve conduction studies):
- Not routinely necessary for diagnosis
- May be useful if asymmetric symptoms or normal examination despite complaints
- Will be normal in small fiber neuropathy (e.g., bortezomib-induced) 5
- Skin biopsy is gold standard for small fiber neuropathy but rarely needed clinically 5
Management Approach
Prevention
No agents are recommended for prevention of CIPN 1. Specifically:
Do NOT offer (strong recommendation):
- Acetyl-L-carnitine (evidence shows harms outweigh benefits) 1
- Calcium/magnesium, amifostine, gabapentin/pregabalin, glutathione, or numerous other agents 1
Insufficient evidence for acupuncture, cryotherapy, compression therapy, or exercise as preventive measures 1
Treatment During Active Chemotherapy
When patients develop intolerable neuropathy and/or functional impairment, clinicians should assess and discuss with patients the appropriateness of:
- Dose delaying
- Dose reduction
- Stopping chemotherapy
- Substituting with non-neurotoxic agents 1
This is critical because continuing treatment can lead to irreversible neuropathy that persists for years.
Treatment After Chemotherapy Completion
For patients with painful CIPN, duloxetine is the ONLY agent with appropriate evidence to support its use (moderate recommendation, though benefit is limited) 1.
Insufficient evidence to recommend:
- Gabapentin/pregabalin
- Tricyclic antidepressants
- Topical compounds (baclofen/amitriptyline/ketamine)
- Oral cannabinoids
- Exercise therapy, acupuncture, or scrambler therapy (preliminary evidence suggests potential benefit but requires larger studies) 1
Critical Pitfalls
Healthcare professionals tend to underestimate symptoms experienced by patients—always use patient-reported outcomes 5
The "coasting phenomenon" with oxaliplatin: Neuropathy worsens for 2-3 months AFTER stopping treatment, so patients need counseling about this expected trajectory 1
Long-term persistence: 42% of patients still have neuropathy 2 years post-treatment—this is not a transient side effect 3
Higher cumulative docetaxel doses (as in sequential AC→T regimens) cause more severe long-term neuropathy compared to concurrent regimens 3
Quality of life impact is substantial: Global QOL scores are significantly lower in patients with CIPN (51.3 vs. 72.6 in those without, p<0.001), with negative correlations between CIPN severity and physical functioning, role functioning, and overall QOL 2